In cell-based and animal studies, GHRH-receptor agonism (tesamorelin) and GHS-R1a agonism (ipamorelin) have been reported to engage different intracellular signaling cascades that both terminate in growth-hormone secretion, an arrangement investigators have explored for potentially amplified, rather than simply additive, secretory responses
The schedules of the entrances and transports could be subject to modifications
If symptoms of low blood sugar occur, eat glucose tablets or gel, corn syrup, honey, or sugar cubes, or drink fruit juice, non-diet soft drink, or sugar dissolved in water to relieve the symptoms
How does testing work
The primary mechanism is therefore identical to Sermorelin (GHRH 1-29) and CJC-1295 (tetra-substituted analog), but pharmacokinetics differ: approximately 8-minute plasma half-life for Tesamorelin via SC route (FDA Egrifta SV label) versus 10-15 min for Sermorelin and 6-8 days for CJC-1295 DAC